FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 206 filers reported holding FATE THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.69 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $40,214,000 | -33.7% | 1,037,256 | 0.0% | 7.85% | +25.1% |
| Q4 2021 | $60,690,000 | -1.3% | 1,037,256 | 0.0% | 6.28% | -16.7% |
| Q3 2021 | $61,478,000 | -32.0% | 1,037,256 | -0.4% | 7.53% | -16.1% |
| Q2 2021 | $90,392,000 | -2.4% | 1,041,507 | -7.3% | 8.98% | +31.9% |
| Q1 2021 | $92,639,000 | -30.2% | 1,123,576 | -23.0% | 6.81% | -5.9% |
| Q4 2020 | $132,714,000 | +42.2% | 1,459,517 | -37.5% | 7.23% | +5.1% |
| Q3 2020 | $93,360,000 | +16.5% | 2,335,750 | 0.0% | 6.88% | -7.8% |
| Q2 2020 | $80,140,000 | +63.5% | 2,335,750 | +5.8% | 7.46% | +33.9% |
| Q1 2020 | $49,023,000 | +9.6% | 2,207,250 | -3.4% | 5.57% | -25.2% |
| Q4 2019 | $44,731,000 | +26.0% | 2,285,714 | 0.0% | 7.46% | +16.2% |
| Q3 2019 | $35,497,000 | – | 2,285,714 | – | 6.41% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |